Alpha Glucosidase Inhibitors Market by Drug class (Acarbose (Precose), Miglitol (Glyset), Voglibose), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2024-2030
Description
Alpha Glucosidase Inhibitors Market by Drug class (Acarbose (Precose), Miglitol (Glyset), Voglibose), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2024-2030
The Alpha Glucosidase Inhibitors Market size was estimated at USD 616.76 million in 2023 and expected to reach USD 703.76 million in 2024, at a CAGR 14.50% to reach USD 1,591.49 million by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Alpha Glucosidase Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alpha Glucosidase Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Alpha Glucosidase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Alkem Laboratories Ltd., Avecia Healthcare, Bal Pharma Ltd., Bayer AG, Biocon, BioVision Inc. by Abcam US Group Holdings Inc., Cipla Ltd., Elder Pharmaceuticals Ltd., Empros Pharma AB, Glenmark Pharmaceuticals Ltd., Lunan Pharmaceuticals Group, Manus Aktteva Biopharma LLP, Merck KGaA, Micro Labs Ltd., Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd., Novo Nordisk A/S, Samex Overseas, Sanofi S.A., Shenzhen Haorui Pharmatech Co., Ltd., Straight Healthcare, Strides Arcolab Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Torrent Pharmaceuticals Ltd., and Wockhardt Ltd..
Market Segmentation & Coverage
This research report categorizes the Alpha Glucosidase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:
Drug class
Acarbose (Precose)
Hospital Pharmacies
Home Healthcare
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Alpha Glucosidase Inhibitors Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alpha Glucosidase Inhibitors Market?
- What are the technology trends and regulatory frameworks in the Alpha Glucosidase Inhibitors Market?
- What is the market share of the leading vendors in the Alpha Glucosidase Inhibitors Market?
- Which modes and strategic moves are suitable for entering the Alpha Glucosidase Inhibitors Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
187 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Alpha Glucosidase Inhibitors Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Prevalence of type 2 diabetes and need for improved care
- 5.1.1.2. Government initiatives and policies encouraging diabetes management
- 5.1.1.3. Increasing focus on combination therapies with alpha-glucosidase inhibitors
- 5.1.2. Restraints
- 5.1.2.1. Difficulties of API approval and dosing regimen
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing R&D activities for new alpha-glucosidase inhibitor discovery
- 5.1.3.2. Personalized medicine approaches for improved alpha-glucosidase inhibitor efficacy
- 5.1.4. Challenges
- 5.1.4.1. Concerns associated with gastrointestinal side effects and drug interactions
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Alpha Glucosidase Inhibitors Market, by Drug class
- 6.1. Introduction
- 6.2. Acarbose (Precose)
- 6.3. Miglitol (Glyset)
- 6.4. Voglibose
- 7. Alpha Glucosidase Inhibitors Market, by Distribution Channel
- 7.1. Introduction
- 7.2. Hospital Pharmacies
- 7.3. Online Pharmacies
- 7.4. Retail Pharmacies
- 8. Alpha Glucosidase Inhibitors Market, by End-Users
- 8.1. Introduction
- 8.2. Home Healthcare
- 8.3. Hospitals & Clinics
- 8.4. Specialty Diabetes Centers
- 9. Americas Alpha Glucosidase Inhibitors Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Alpha Glucosidase Inhibitors Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Alpha Glucosidase Inhibitors Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Alkem Laboratories Ltd.
- 13.1.2. Avecia Healthcare
- 13.1.3. Bal Pharma Ltd.
- 13.1.4. Bayer AG
- 13.1.5. Biocon
- 13.1.6. BioVision Inc. by Abcam US Group Holdings Inc.
- 13.1.7. Cipla Ltd.
- 13.1.8. Elder Pharmaceuticals Ltd.
- 13.1.9. Empros Pharma AB
- 13.1.10. Glenmark Pharmaceuticals Ltd.
- 13.1.11. Lunan Pharmaceuticals Group
- 13.1.12. Manus Aktteva Biopharma LLP
- 13.1.13. Merck KGaA
- 13.1.14. Micro Labs Ltd.
- 13.1.15. Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd.
- 13.1.16. Novo Nordisk A/S
- 13.1.17. Samex Overseas
- 13.1.18. Sanofi S.A.
- 13.1.19. Shenzhen Haorui Pharmatech Co., Ltd.
- 13.1.20. Straight Healthcare
- 13.1.21. Strides Arcolab Limited
- 13.1.22. Sun Pharmaceutical Industries Ltd.
- 13.1.23. Takeda Pharmaceutical Co. Ltd.
- 13.1.24. Torrent Pharmaceuticals Ltd.
- 13.1.25. Wockhardt Ltd.
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. ALPHA GLUCOSIDASE INHIBITORS MARKET RESEARCH PROCESS
- FIGURE 2. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2023 VS 2030
- FIGURE 3. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ALPHA GLUCOSIDASE INHIBITORS MARKET DYNAMICS
- FIGURE 7. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
- FIGURE 8. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 10. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
- FIGURE 12. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ALPHA GLUCOSIDASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. ALPHA GLUCOSIDASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
